- Home
- NODK vs GUTS Comparison
NODK vs GUTS Comparison
Compare NODK & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- GUTS
- Stock Information
- Founded
- NODK 1946
- GUTS 2010
- Country
- NODK United States
- GUTS United States
- Employees
- NODK N/A
- GUTS N/A
- Industry
- NODK Property-Casualty Insurers
- GUTS
- Sector
- NODK Finance
- GUTS
- Exchange
- NODK Nasdaq
- GUTS NYSE
- Market Cap
- NODK 265.4M
- GUTS 58.8M
- IPO Year
- NODK 2017
- GUTS 2024
- Fundamental
- Price
- NODK $13.12
- GUTS $1.67
- Analyst Decision
- NODK
- GUTS Buy
- Analyst Count
- NODK 0
- GUTS 1
- Target Price
- NODK N/A
- GUTS $10.00
- AVG Volume (30 Days)
- NODK 19.7K
- GUTS 942.7K
- Earning Date
- NODK 08-07-2025
- GUTS 08-13-2025
- Dividend Yield
- NODK N/A
- GUTS N/A
- EPS Growth
- NODK N/A
- GUTS N/A
- EPS
- NODK N/A
- GUTS N/A
- Revenue
- NODK $322,139,000.00
- GUTS $60,000.00
- Revenue This Year
- NODK N/A
- GUTS N/A
- Revenue Next Year
- NODK N/A
- GUTS N/A
- P/E Ratio
- NODK $43.73
- GUTS N/A
- Revenue Growth
- NODK 3.15
- GUTS N/A
- 52 Week Low
- NODK $12.01
- GUTS $0.87
- 52 Week High
- NODK $17.24
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- NODK 53.71
- GUTS 44.68
- Support Level
- NODK $12.76
- GUTS $1.56
- Resistance Level
- NODK $13.11
- GUTS $1.82
- Average True Range (ATR)
- NODK 0.46
- GUTS 0.16
- MACD
- NODK 0.04
- GUTS -0.05
- Stochastic Oscillator
- NODK 72.53
- GUTS 16.15
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.